October 28, 2016
Teva IBM join forces on finding new uses for drugs
IBM and Teva Pharmaceutical Industries Ltd., are expanding their global e-Health alliance to focus on the discovery of new treatment …
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Michael Hayden
November 26, 2015
Teva to receive global development and commercial rights to Hemtares’ novel CGRP antagonists
Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Sosei Group’s subsidiary Heptares, for the treatment of migraine.